Subscribe for $2

Subscribe for 2 $

Financial Data API

BLACK WEEK: SAVE 600 €

EULERPOOL LIFETIME ACCESS — 50 % Rabatt

Terminal Financial Data API

Takeda Pharmaceutical Co Aktie News & Pressemeldungen

Takeda Pharmaceutical Co Eulerpool News

12/4/2024, 12:12:22 PM

Takeda stärkt Onkologie-Portfolio durch Lizenzvereinbarung mit Keros Therapeutics

12/3/2024, 8:35:53 PM

Takeda und Keros: Partnerschaft zur globalen Vermarktung von Elritercept

11/29/2024, 8:22:52 PM

Takeda Canada stärkt innovative Forschung im Bereich entzündlicher Darmerkrankungen

11/29/2024, 4:46:01 PM

Innovationsschub in der IBD-Forschung: Takeda Kanada unterstützt bedeutende Studien

11/25/2024, 6:40:23 PM

Neuer Hoffnungsträger im Kampf gegen Multiples Myelom: Blenreps Rückkehr

1

2

1

2

Takeda Pharmaceutical Co Stock News

Takeda Pharmaceutical Co is being monitored by journalists and investors worldwide. We gather the latest Takeda Pharmaceutical Co news here.

December 4 ·
Yahoo
Novavax sells Czech plant to Novo; Relay licenses out a cancer drug
December 4 ·
Yahoo
Takeda licensed for anaemia therapy by Keros Therapeutics
December 3 ·
Yahoo
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
December 3 ·
Yahoo
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
December 3 ·
Yahoo
Takeda’s Strong FY2024 H1 Boosts Full-Year Outlook
November 30 ·
Yahoo
Why Takeda (TAK) Is One of the Most Profitable Pharmaceutical Stocks Right Now?
November 29 ·
Yahoo
Takeda Canada co-sponsors grant to boost IBD clinical research
November 28 ·
SeekingAlpha
Alumis: A Best-In-Class TYK2 Inhibitor
November 22 ·
Yahoo
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
November 21 ·
Yahoo
Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies

1

2

1

2

Takeda Pharmaceutical Co Stock Press Releases

Takeda Pharmaceutical Co regularly publishes news on the company's website that are relevant for investors.

Access the world's leading financial data and tools

Subscribe for $2